Table 2.
The sensitivities and specialties of DNA methylation, ETCs detection and the combined assays on lung cancer patients.
| Group | AUC (95% CI) |
Sensitivity% (SE) | Specificity% (SP) |
|---|---|---|---|
| RASSF1A | 0.679 (0.515–0.816) | 46.9 (29.1–65.3) | 88.9 (51.8–99.7) |
| SHOX2 | 0.724 (0.562–0.852) | 78.1 (60.0–90.7) | 66. 7 (29.9–92.5) |
| ETCs | 0.532 (0.394 –0.667) | 84.2 (68.7–94.0) | 22.2 (6.4–47.6) |
| RASSF1A/SHOX2 | 0.731 (0.570–0.857) | 90.6 (75.0–98.0) | 55.6 (21.2–86.3) |
| RASSF1A + SHOX2 | 0.672 (0.508–0.810) | 34.4 (18.6–53.2) | 100.0 (66.4–100.0) |
| RASSF1A/SHOX2 + ETCs | 0.759 (0.579–0.890) | 92.6 (75.7–99.1) | 50.0 (11.8–88.2) |
| RASSF1A + SHOX2 + ETCs | 0.778 (0.600–0.903) | 55.6 (35.3–74.5) | 100.0 (54.1–100.0) |
AUC = area under the curve, ETCs = exfoliated tumor cells, RASSF1A = the RAS association domain family 1, isoform A, SHOX2 = the short stature homeobox gene 2.